hepatitis web study hepatitis web study sofosbuvir + additional agents electron (overview): 6 parts,...

4

Hepati tis web study Hepati tis web study Sofosbuvir + Additional Agents ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced Source: Clinical Trials.gov

Upload: cameron-richard

Post on 28-Dec-2015

214 views

Category:

Documents

0 download

Report

Download

Tags:

Embed Size (px):

TRANSCRIPT

Page 1: Hepatitis web study Hepatitis web study Sofosbuvir + Additional Agents ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced

Hepatitisweb study

Hepatitisweb study

Sofosbuvir + Additional AgentsELECTRON (Overview): 6 parts, 22 arms

Phase 2

Treatment Naïve and Treatment Experienced

Source: Clinical Trials.gov

Page 2: Hepatitis web study Hepatitis web study Sofosbuvir + Additional Agents ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced

Hepatitisweb study

SofosbuvirSummary of ELECTRON Trials Design (1 of 2)

• Part 1 - Arm 1: Sofosbuvir + Ribavirin x 12 weeks (GT 2,3; naive)- Arm 2: Sofosbuvir + Ribavirin x 12 weeks + Peginterferon for weeks 1-4 (GT 2,3; naive) - Arm 3: Sofosbuvir + Ribavirin x 12 weeks + Peginterferon for weeks 1-8 (GT 2,3; naive)- Arm 4: Sofosbuvir + Ribavirin + Peginterferon x 12 weeks (GT 2,3; naive)

• Part 2- Arm 5: Sofosbuvir x 12 weeks (GT 2,3; naive)- Arm 6: Sofosbuvir + Ribavirin + Peginterferon x 8 weeks (GT 2,3; naive)- Arm 7: Sofosbuvir + Ribavirin x 12 weeks (GT 1; experienced null)

• Part 3- Arm 8: Sofosbuvir + Ribavirin x 12 weeks (GT 1; naive)- Arm 9: Sofosbuvir + Ribavirin x 12 weeks (GT 2,3; experienced)

• Part 4- Arm 10: Sofosbuvir + Ribavirin x 8 weeks (GT 2,3; naive)- Arm 11: Sofosbuvir + Ribavirin x 12 weeks (GT 2,3; naive)- Arm 12: Sofosbuvir + Ledipasvir + Ribavirin x 12 weeks (GT 1, experienced null)- Arm 13: Sofosbuvir + Ledipasvir + Ribavirin x 12 weeks (GT 1, naive)

Source: ClinicalTrials.gov ID NCT01260350

Page 3: Hepatitis web study Hepatitis web study Sofosbuvir + Additional Agents ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced

Hepatitisweb study

SofosbuvirSummary of ELECTRON Trials Design (2 of 2)

• Part 5 - Arm 14: Sofosbuvir + GS-9669 + Ribavirin x 12 weeks (GT 1; experienced null)- Arm 15: Sofosbuvir + GS-9669 + Ribavirin x 12 weeks x 12 weeks (GT 1; naive)

• Part 6- Arm 16: Sofosbuvir-Ledipasvir x 12 weeks (GT 1; experienced null; F4)- Arm 17: Sofosbuvir-Ledipasvir + Ribavirin x 12 weeks (GT 1; experienced null; F4)- Arm 18: Sofosbuvir-Ledipasvir x 12 weeks x 12 weeks (GT 2,3, naive)- Arm 19: Sofosbuvir-Ledipasvir x 12 weeks x 12 weeks (GT 2,3, experienced)- Arm 20: Sofosbuvir-Ledipasvir + Ribavirin x 12 weeks (GT 1, naïve, hemophiliacs)- Arm 21: Sofosbuvir-Ledipasvir + Ribavirin x 6 weeks (GT 1, naive)- Arm 22: Sofosbuvir-Ledipasvir x 6 weeks (GT 1, naive)

Source: ClinicalTrials.gov ID NCT01260350

Page 4: Hepatitis web study Hepatitis web study Sofosbuvir + Additional Agents ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced

Hepatitisweb study

Hepatitisweb study

This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects.

Hepatitis C Online

www.hepatitisc.uw.edu

Hepatitis Web Study

http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.

http://www.hepatitisc.uw.edu/

http://depts.washington.edu/hepstudy/

http://depts.washington.edu/hepstudy/

http://depts.washington.edu/hepstudy/

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir Retreatment with HCV Genotype 1 NIAID Retreatment Phase 2a Treatment Experienced Osinusi

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C · Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Application for inclusion on the WHO Model List of Essential Medicines

Attachment: Product Information: Sofosbuvir / … · Web viewc.In clinical trials, prior treatment experience included sofosbuvir with or without any of the following: peginterferon

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline

Hepatitis web study Hepatitis web study Sofosbuvir, Ribavirin, GS-0938 in GT 1-4 QUANTUM Phase 2b Treatment Naïve Lalezari JP, et al. EASL. 2013; Abstract

Hepatitis web study Hepatitis web study Sofosbuvir + (Ledipasvir or GS-9669) +/- Ribavirin in GT-1 ELECTRON Trial (Arms 12-17 & 22) Phase 2 Treatment Naïve

Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial...Hepatitis web study Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial Phase 3 Treatment Naïve and Treatment

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced HCV GT1 Retreatment of Sofosbuvir Failures Phase 2 Treatment

Sofosbuvir for the treatment of patients with genotype 2 or 3 … · 2019-07-12 · Clin. Invest. (2014) 4(4), 361–371 ISSN 2041-6792 361 Treatment of chronic hepatitis C will dramatically

Updates on hepatitis B and C treatment guidelines and ... on hepatitis B and C treatment guidelines and overview of hepatitis treatment landscape Philippa Easterbrook

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2 Phase 2 Treatment Experienced Lawitz E, et

PROGRAM · Real-world effectiveness of ledipasvir/sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: single-center experience within Georgian hepatitis C elimination program

204671Orig1s000 · Applicant’s letter date: April 6, 2013 . CDER stamp date: April 8, 2013 . Product: Sofosbuvir (GS-7977) Indication: Treatment of chronic hepatitis C in combination

RETREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH …...ilc2019 poster presented at: effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis

Treatment of chronic hepatitis C virus infection - NAMCP · Treatment of chronic hepatitis C virus infection ... Gilead, Janssen, ... (n=134) Sofosbuvir + RBV (n=132) Phase 3 Open-label

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Phase 2 Treatment

Viral Hepatitis: A Global Snapshot of Challenges and ...iapac.org/icvh/presentations/ICVH2016_Plenary1_Ward.pdf · Price (US$) Ledipasvir-sofosbuvir Sofosbuvir Simeprevir Daclatasvir

Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced

5.01.606 Hepatitis C Antiviral Therapy - Premera Blue Cross · pegylated interferon, ribavirin, and/or sofosbuvir but no prior treatment experience with an NS3/4A PI or NS5A inhibitor

Hepatitis web study Hepatitis web study Sofosbuvir ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced Source: Gilead

Hepatitis web study Hepatitis web study Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* Phase 3 *Note: Published in NEJM in tandem with

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C...regimen for the treatment of chronic hepatitis C (HCV) genotypes 1-6 in adults. [1] Velpatasvir is a NS5A inhibitor, preventing

Doctors of the WorlD opposes the patent on sofosbuvir ... · What is hepatitis C? Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) and primarily blood-born transmitted

Australian Public Assessment Report for: Sofosbuvir ... · treatment of chronic hepatitis C virus (HCV) infection in adults. Velpatasvir is a new chemical entity whereas sofosbuvir

Sofosbuvir + PEG + RBV in Treatment-Naïve HCV GT 1,4,5,6 NEUTRINO Trial*

Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A1444-040 Trial Phase 2a Treatment Naïve and Treatment

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1 … › hepstudy › presentations › ...Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 A1444040 Trial

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir +/- Ribavirin in Genotype 1 COSMOS Trial Phase 2a, Treatment Naïve and Treatment Experienced

Médecins du Monde opposes the patent on sofosbuvir …What is hepatitis C? Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) and primarily blood-born transmitted

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology. 2015;148:100-7